Laboratory investigation results influence Physician's Global Assessment (PGA) of disease activity in SLE

被引:25
作者
Aranow, Cynthia [1 ]
Askanase, Anca [2 ]
Oon, Shereen [3 ]
Huq, Molla [4 ]
Calderone, Alicia [3 ]
Morand, Eric F. [5 ]
Nikpour, Mandana [3 ]
机构
[1] Feinstein Inst Med Res, Manhasset, NY 11030 USA
[2] Columbia Univ Coll Phys & Surg, Rheumatol, 630 W 168th St, New York, NY 10032 USA
[3] St Vincents Hosp, Rheumatol, Fitzroy, Vic, Australia
[4] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
[5] Monash Univ, Sch Clin Sci, Clayton, Vic, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
disease activity; outcomes research; systemic lupus erythematosus;
D O I
10.1136/annrheumdis-2019-216753
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To evaluate the impact of laboratory results on scoring of the Physician Global Assessment (PGA) of disease activity in systemic lupus erythematosus. Methods Fifty clinical vignettes were presented via an online survey to a group of international lupus experts. For each case, respondents scored the PGA pre and post knowledge of laboratory test results (pre-lab and post-lab PGAs). Agreement between individual assessors and relationships between pre-lab and post-lab PGAs, and PGAs and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) were determined. Respondents were also asked about factors they incorporate into their PGA determinations. Results Sixty surveys were completed. The inter-rater PGA reliability was excellent (pre-lab intraclass correlation coefficient (ICC) 0.98; post-lab ICC 0.99). Post-lab PGAs were higher than pre-lab PGAs: median (IQR) pre-lab PGA 0.5 (1.05), post-lab PGA 1 (1.3) (p<0.001), with a median (IQR) difference of 0.2 (0.45). In general, all abnormal labs including elevated anti-double stranded DNA antibody level (dsDNA) and low complement impacted PGA assessment. Cases with weakest correlations between pre-lab and post-lab PGA were characterised by laboratory results revealing nephritis and/or haematological manifestations. Both pre-lab and post-lab PGAs correlated with SLEDAI-2K. However, a significantly stronger correlation was observed between post-lab PGA and SLEDAI-2K. Multiple factors influenced PGA determinations. Some factors were considered by an overwhelming majority of lupus experts, with less agreement on others. Conclusions We found excellent inter-rater reliability for PGAs in a group of international lupus experts. Post-lab PGA scores were higher than pre-lab PGA scores, with a significantly stronger correlation with the SLEDAI-2K. Our findings indicate that PGA scoring should be performed with knowledge of pertinent laboratory results.
引用
收藏
页码:787 / 792
页数:6
相关论文
共 7 条
[1]   A pilot study to determine the optimal timing of the Physician Global Assessment (PGA) in patients with systemic lupus erythematosus [J].
Aranow, Cynthia .
IMMUNOLOGIC RESEARCH, 2015, 63 (1-3) :167-169
[2]   Definition and initial validation of a Lupus Low Disease Activity State (LLDAS) [J].
Franklyn, Kate ;
Lau, Chak Sing ;
Navarra, Sandra V. ;
Louthrenoo, Worawit ;
Lateef, Aisha ;
Hamijoyo, Laniyati ;
Wahono, C. Singgih ;
Chen, Shun Le ;
Jin, Ou ;
Morton, Susan ;
Hoi, Alberta ;
Huq, Molla ;
Nikpour, Mandana ;
Morand, Eric F. .
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (09) :1615-1621
[3]   Novel Evidence-Based Systemic Lupus Erythematosus Responder Index [J].
Furie, Richard A. ;
Petri, Michelle A. ;
Wallace, Daniel J. ;
Ginzler, Ellen M. ;
Merrill, Joan T. ;
Stohl, William ;
Chatham, W. Winn ;
Strand, Vibeke ;
Weinstein, Arthur ;
Chevrier, Marc R. ;
Zhong, Z. John ;
Freimuth, William W. .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (09) :1143-1151
[4]   Combined oral contraceptives in women with systemic lupus erythematosus [J].
Petri, M ;
Kim, MY ;
Kalunian, KC ;
Grossman, J ;
Hahn, BH ;
Sammaritano, LR ;
Lockshin, M ;
Merrill, JT ;
Belmont, HM ;
Askanase, AD ;
McCune, WJ ;
Hearth-Holmes, M ;
Dooley, MA ;
Von Feldt, J ;
Friedman, A ;
Tan, M ;
Davis, J ;
Cronin, M ;
Diamond, B ;
Mackay, M ;
Sigler, L ;
Fillius, M ;
Rupel, A ;
Licciardi, F ;
Buyon, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (24) :2550-2558
[5]  
PETRI M, 1992, J RHEUMATOL, V19, P53
[6]   A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS) [J].
van Vollenhoven, Ronald ;
Voskuyl, Alexandre ;
Bertsias, George ;
Aranow, Cynthia ;
Aringer, Martin ;
Arnaud, Laurent ;
Askanase, Anca ;
Balazova, Petra ;
Bonfa, Eloisa ;
Bootsma, Hendrika ;
Boumpas, Dimitrios ;
Bruce, Ian ;
Cervera, Ricard ;
Clarke, Ann ;
Coney, Cindy ;
Costedoat-Chalumeau, Nathalie ;
Czirjak, Laszlo ;
Derksen, Ronald ;
Doria, Andrea ;
Doerner, Thomas ;
Fischer-Betz, Rebecca ;
Fritsch-Stork, Ruth ;
Gordon, Caroline ;
Graninger, Winfried ;
Gyori, Noemi ;
Houssiau, Frederic ;
Isenberg, David ;
Jacobsen, Soren ;
Jayne, David ;
Kuhn, Annegret ;
Le Guern, Veronique ;
Lerstrom, Kirsten ;
Levy, Roger ;
Machado-Ribeiro, Francinne ;
Mariette, Xavier ;
Missaykeh, Jamil ;
Morand, Eric ;
Mosca, Marta ;
Inanc, Murat ;
Navarra, Sandra ;
Neumann, Irmgard ;
Olesinska, Marzena ;
Petri, Michelle ;
Rahman, Anisur ;
Rekvig, Ole Petter ;
Rovensky, Jozef ;
Shoenfeld, Yehuda ;
Smolen, Josef ;
Tincani, Angela ;
Urowitz, Murray .
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (03) :554-561
[7]   Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study [J].
Wallace, Daniel J. ;
Kalunian, Kenneth ;
Petri, Michelle A. ;
Strand, Vibeke ;
Houssiau, Frederic A. ;
Pike, Marilyn ;
Kilgallen, Brian ;
Bongardt, Sabine ;
Barry, Anna ;
Kelley, Lexy ;
Gordon, Caroline .
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) :183-190